the impact of trk inhibitor loxo-101 (larotrectinib) on patients with trk fusion cancers
Published 7 years ago • 1K plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
1:15
larotrectinib, a trk inhibitor for patients with solid tumors
-
0:54
efficacy results for loxo-101 in trk fusion cancers
-
1:13
larotrectinib in patients with trk fusion salivary gland tumours
-
4:36
trk inhibition: personal experience with larotrectinib
-
5:20
trk inhibitor in gi cancers: adverse effect profile
-
1:29
dr. demetri on larotrectinib in trk-fusion gi cancers
-
6:02
early development of trk inhibitor–larotrectinib
-
1:20
updated data with larotrectinib in trk fusion-positive solid tumors
-
3:30
favorable safety profile in novel trk inhibitor
-
2:55
entrectinib’s value as a trk inhibitor
-
3:20
approaching treatment for trk fusion–positive cancers
-
2:53
other approaches to trk-fusion cancers
-
6:00
efficacy of trk inhibitors
-
7:14
larotrectinib for solid tumors with ntrk gene fusions
-
4:07
trk inhibition: ongoing challenges
-
5:21
cornelis van tilburg, asco 2019 - larotrectinib in pediatric trk fusion cancer
-
5:08
larotrectinib for ntrk fusions: patient selection
-
0:45
examining response rates in msi-h and ntrk fusion gi cancers
-
4:09
moving forward with trk inhibition